Literature DB >> 19120045

Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome.

D J Smith1, L Forty, E Russell, S Caesar, J Walters, C Cooper, I Jones, L Jones, N Craddock.   

Abstract

OBJECTIVE: A small but significant proportion of patients with major depressive disorder (MDD) report mild manic symptoms which are below the diagnostic threshold for a hypomanic episode.
METHOD: We tested for an association between sub-threshold manic symptoms and clinical outcome in almost 600 patients with recurrent MDD who also had no known family history of bipolar disorder.
RESULTS: 9.6% of this large sample had a life-time history of sub-threshold manic symptoms. These patients were significantly more likely to have a history of poor response to antidepressants (OR 2.84; 95% CI 1.23-6.56; P < 0.02) and more likely to have experienced psychosis (OR 2.07; 95% CI 1.05-4.09; P < 0.04). They had also experienced more depressive episodes on average (P = 0.006) and were more likely to have been admitted to hospital (P < 0.03).
CONCLUSION: Sub-threshold manic symptoms in patients with recurrent MDD may be a useful clinical marker for poor response to antidepressants and a more morbid long-term clinical course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120045     DOI: 10.1111/j.1600-0447.2008.01324.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

1.  Bipolar spectrum disorders in primary care: optimising diagnosis and treatment.

Authors:  Daniel J Smith; Ajay Thapar; Sharon Simpson
Journal:  Br J Gen Pract       Date:  2010-05       Impact factor: 5.386

2.  Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.

Authors:  Manish K Jha; Ashley L Malchow; Bruce D Grannemann; A John Rush; Madhukar H Trivedi
Journal:  Neuropsychopharmacology       Date:  2018-08-15       Impact factor: 7.853

Review 3.  Rethinking the spectrum of mood disorders: implications for diagnosis and management - Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France.

Authors:  Roger S McIntyre; Allan H Young; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-25

4.  Validation of the 33-Item Hypomania Checklist-External Assessment in Screening Adolescents for Bipolar Disorder.

Authors:  Xu Chen; Hong Cai; Wei Bai; Sha Sha; Teris Cheung; Gabor S Ungvari; Yuan Feng; Yu-Tao Xiang; Jules Angst
Journal:  Front Psychiatry       Date:  2022-06-15       Impact factor: 5.435

5.  Should major depressive disorder with mixed features be classified as a bipolar disorder?

Authors:  Xiaohua Liu; Kaida Jiang
Journal:  Shanghai Arch Psychiatry       Date:  2014-10

6.  The Differential Levels of Inflammatory Cytokines and BDNF among Bipolar Spectrum Disorders.

Authors:  Tzu-Yun Wang; Sheng-Yu Lee; Shiou-Lan Chen; Yi-Lun Chung; Chia-Ling Li; Yun-Hsuan Chang; Liang-Jen Wang; Po See Chen; Shih-Heng Chen; Chun-Hsien Chu; San-Yuan Huang; Nian-Sheng Tzeng; Tsai-Hsin Hsieh; Yen-Chu Chiu; I Hui Lee; Kao-Chin Chen; Yen Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.